NCT06163989 Protecting the Eyes of Gamers With Lubricating Eyedrops
| NCT ID | NCT06163989 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Aston University |
| Condition | Dry Eye Syndromes |
| Study Type | INTERVENTIONAL |
| Enrollment | 28 participants |
| Start Date | 2024-09-01 |
| Primary Completion | 2026-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 28 participants in total. It began in 2024-09-01 with a primary completion date of 2026-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The excessive use of screens particularly amongst digital gamers can adversely impact the health of the surface of the eyes with symptoms and signs of surface damage. While strategies including limiting screen time exist, these may be ineffective given the widespread rise of digital device use and gaming culture in the modern era. There is limited evidence for the protective effect of lubricating eyedrops on the ocular surface for handheld console and computer gamers. The aim of this study is to investigate the protective effect of a lubricating eyedrop (TheaLoz Duo) on the surface of the eyes in handheld console and computer gamers. The main question it aims to answer is whether TheaLoz Duo could protect the surface of the eyes from dessication and alleviate symptoms of dry eye disease in handheld console and computer gamers. Participants will receive either the lubricating eyedrop first for 1 month, followed by a control condition (no eyedrops) for another month, or the other way round. Participants will attend 3 visits in total, each separated by 1 month apart. During each visit, routine clinical assessments of the front of the eye will be conducted. Subsequent findings from this timely study will help improve care of the surface of the eyes for a growing population of gamers worldwide.
Eligibility Criteria
Inclusion criteria: * Individuals with dryness symptoms as assessed with the Ocular Surface Disease Index (OSDI score ≥ 13). * Individuals who play handheld console and computer-based games ≥ 2 hours everyday on average * Individuals who are comfortable and competent at using smartphone applications * Age ≥ 18 years, male or female * Able to provide written consent in English * Able to instil the treatment lubricating eyedrop on their own, and return any provided eyedrop bottle to the researcher used at the end of the treatment * Able to attend multiple visits (3 visits over 2 months) Exclusion criteria: * Pregnancy * Use of any topical ocular medical eyedrops or lubricants in the 1 week prior to starting the study or during the study period. Those who are using existing lubricating eyedrops and are interested in participating will be required to stop their lubricating eyedrops for 1 week prior to commencing the study * History of ocular surgery, trauma or infections in the past 6 months
Contact & Investigator
James S Wolffsohn, PhD
STUDY DIRECTOR
Aston University
Frequently Asked Questions
Who can join the NCT06163989 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Dry Eye Syndromes. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06163989 currently recruiting?
Yes, NCT06163989 is actively recruiting participants. Contact the research team at dryeye@aston.ac.uk for enrollment information.
Where is the NCT06163989 trial being conducted?
This trial is being conducted at Birmingham, United Kingdom.
Who is sponsoring the NCT06163989 clinical trial?
NCT06163989 is sponsored by Aston University. The principal investigator is James S Wolffsohn, PhD at Aston University. The trial plans to enroll 28 participants.